Catalent Present on Drug Delivery, Formulation & Patient-Focused Design at AAPS
SOMERSET, N.J. – November 9, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it will host and present multiple industry-centric discussions, present scientific papers, and exhibit at the forthcoming 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs from Nov. 12 -15, at the San Diego Convention Center, San Diego.
As well as exhibiting and showcasing its multiple innovative technologies, Catalent will be participating in the following scientific presentations:
On Monday, Nov. 13, Catalent will host a “Lunch and Learn” session at 12 p.m., entitled, “Drug Delivery 2017: The Path Ahead.” Cornell Stamoran, Ph.D., founder and co-chair of the Catalent Applied Drug Delivery Institute and VP Corporate Strategy, and Ronak Savla, Pharm.D., Ph.D., Scientific Affairs Manager, will moderate informal discussions on current and future drug delivery trends, and why we need to consider the patient’s voice during formulation development.
Later that afternoon, at 2 p.m., Catalent will present a symposium entitled “Patient Focused Drug Design,” including an overview of patient and stakeholder needs, discussion of strategies to incorporate these considerations at the formulation stage, and why these approaches make good business sense. Presentations will be given by experts Cornell Stamoran and Stephen Tindal of Catalent, joined by drug delivery experts Dr. Keith Horspool and Dr. Ralph Niven, and Mike Rea, Chief Executive Officer of IDEA Pharma.
Julien Meissonnier, VP, Science & Technology, will also be presenting “Formulation Approaches to Enhance Bioavailability of Oral Anticancer Drugs” that afternoon at 4 p.m. The presentation will discuss how many targeted small molecule drugs for oncology treatments carry black box warnings on their labels, and how formulation can overcome the biopharmaceutical and pharmacokinetic challenges of oral anticancer drugs, and lead to better patient outcomes.
On Tuesday, Nov. 14, Catalent will be hosting a two-part workshop starting at 1 p.m., entitled, “Start Earlier, Move Faster: Smart Drug Development & Design from Candidate to Phase I.” During this session, multiple speakers will present on a range of topics focusing on the transition of a molecule from discovery to phase I readiness. The workshop is structured to be highly interactive and includes case studies that will ask the audience to work in teams to develop solutions. Part one of the workshop will provide an overview of the state of the industry and the tools and techniques used to characterize and assess an API molecule; and part two will give the audience the opportunity to learn strategies for enhancing API bioavailability during the pre-clinical stages and getting into early clinical studies. For the workshop, Edward Narke, Principal at DSI InPharmatics will be joining Catalent experts to present.
Catalent will also present 26 scientific posters at the AAPS meeting on a wide range of topics.
To arrange a meeting with any of the Catalent team at AAPS, please contact Richard Kerns at NEPR- richard@nepr.eu
Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com